Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Brian G. Feagan(Western University), Paul Rutgeerts(KU Leuven), Joshua R. Friedman(Spark Therapeutics (United States)), Stephen B. Hanauer(Northwestern University), Bruce Salzberg(Atlanta Gastroenterology Associates), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Séverine Vermeire(KU Leuven), Ursula Seidler(Medizinische Hochschule Hannover), William J. Sandborn(University of San Diego), Levinus A. Dieleman(University of North Carolina at Chapel Hill), Seymour Katz(New York University), Yinghua Lang, Stephan R. Targan(Cedars-Sinai Medical Center), Marion Blank(Janssen (United States)), Edward V. Loftus(Mayo Clinic), Pierre Desreumaux(Active Biotech (Sweden)), Scott D. Lee(University of Washington), Long-Long Gao(Janssen (United States)), Miao Ye(Western University), Subrata Ghosh(University College Cork), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Zsolt Tulassay(Semmelweis University), Willem J. de Villiers(Western University), Omoniyi J. Adedokun(Western University), Jewel Johanns(Johnson & Johnson (United States)), Christopher Gasink(Janssen (United States))
Cited by 1,836
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k